Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole and Hydrocortisone for Antiandrogen Withdrawal in Advanced Prostate Cancer
NCT00002760Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 1996
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ketoconazole in prostate cancer (PCa) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Prostate-Specific Antigen Response. Started Aug 1996; status: completed.
02
Drugs
ketoconazole
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00002760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002760.